<DOC>
	<DOC>NCT00537017</DOC>
	<brief_summary>The purpose of this study is to assess the long term safety of SCH 420814 (preladenant) in participants with moderate to severe Parkinson's Disease who are taking an L-Dopa/dopa decarboxylase inhibitor and/or dopamine agonist. All participants must have participated in the main study (P04501; NCT00406029) entitled "A Phase 2, 12 Week, Double Blind, Dose Finding, Placebo Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias."</brief_summary>
	<brief_title>Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Participants must have participated in P04501. Participants must be &gt;=30 years of age, with a diagnosis of moderate to severe idiopathic Parkinson's disease. Participants must have been on a regimen of LDopa and/or a dopamine agonist. Participants who discontinued from Study P04501 because they experienced a serious adverse event (SAE) Participants with any form of druginduced or atypical parkinsonism, cognitive impairment, or psychosis Participants taking tolcapone Participants who are participating in any other clinical study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>